top of page
The Professional Network for Healthcare Experts
Lupin licenses European rights to Tenpoint's YUVEZZI for presbyopia
The agreement expands Lupin's European ophthalmology portfolio by adding the first once-daily dual-agent eye drop approved for presbyopia while strengthening its specialty eye care strategy.
nuaxia
21 hours ago3 min read
Lupin licenses two oncology programmes to Kaveri Therapeutics for an 82.2% equity stake
The spin-out creates a dedicated US oncology company to raise capital and advance Lupin’s PRMT5 and SOS1 programmes through global clinical development.
nuaxia
Jul 222 min read
bottom of page